Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715039 · ClinicalTrials.gov registry record · NA
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
A NA study, sponsored by Pfizer.
- Completed
- Registry status
- NA
- Development phase
- 169
- Enrollment target
NCT00715039: Completed NA study, sponsored by Pfizer.
NCT00715039 is a NA study that has completed, run by Pfizer. The registered enrollment target is 169 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00715039, a NA study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- NA
- Development phase
- 169 participants
- Enrollment target
Study Summary
The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
Interventions
- DRUG placebo
- DRUG paroxetine
- DRUG lorazepam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2003-10 |
| Est. Completion | 2004-05 |
| Phase | NA |
What the finished NCT00715039 record still lists
NCT00715039 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00715039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00715039 about?
NCT00715039 is a clinical study titled "Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder". The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
What is the current status of trial NCT00715039?
This trial is currently completed. It is a NA study. The enrollment target is 169 participants. The study started on 2003-10. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00715039?
The interventions under investigation include: placebo (DRUG), paroxetine (DRUG), lorazepam (DRUG).
Who is sponsoring clinical trial NCT00715039?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00715039's enrollment target sits among peer trials
169 619th of 2000 higher than 1,382 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia